Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,718,981 papers from all fields of science
Search
Sign In
Create Free Account
motesanib
An orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (1)
Imetelstat
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
motesanib diphosphate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A Patient with an Advanced Medullary Thyroid Cancer and Progressive, Symptomatic Distant Metastases: When to Start Systemic Therapy
C. Giani
,
A. Matrone
,
R. Elisei
Thyroid Cancer
2020
Corpus ID: 78436138
We present the case of a male patient who presented with what appeared to be sporadic medullary thyroid cancer (MTC) but, with…
Expand
Review
2015
Review
2015
Перспективы терапевтического воздействия на сигнальный путь FGFR
Михаил Юрьевич Федянин
,
Д. Н. Хмелькова
,
Татьяна Сауловна Серебрийская
,
Т. А. Никольская
,
С. А. Тюляндин
2015
Corpus ID: 74482463
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are involved in key cellular functions and cancerogenesis. Nowadays…
Expand
2013
2013
Angiogenesis and Lung Cancer
S. Vázquez
,
U. Anido
,
+5 authors
L. Aparicio
2013
Corpus ID: 49554699
Tumors acquire blood vessels by co-option of neighboring vessels from sprouting or intus‐ suscepted microvascular growth and by…
Expand
2013
2013
Chapter 1 Angiogenesis and Lung Cancer
S. Vázquez
,
U. Anido
,
+5 authors
L. Aparicio
2013
Corpus ID: 8152770
Tumors acquire blood vessels by co-option of neighboring vessels from sprouting or intus‐ suscepted microvascular growth and by…
Expand
Review
2013
Review
2013
Title The effect of different dosing regimens of motesanib on the gallbladder : a randomized phase 1 b study in patients with advanced solid tumors Permalink
L. Rosen
,
L. Lipton
,
+9 authors
N. Tebbutt
2013
Corpus ID: 44167428
Background: Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small…
Expand
2010
2010
Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).
N. Tebbutt
,
D. Kotasek
,
+7 authors
D. Goldstein
2010
Corpus ID: 78363748
3538 Background: Motesanib is an oral inhibitor of VEGF, PDFG, and Kit receptors. Pmab, a fully human monoclonal antibody against…
Expand
2010
2010
Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer.
A. Gramza
,
J. Patterson
,
J. Peters
,
Michael D. Kaufman
,
S. Wise
,
D. Flynn
2010
Corpus ID: 74482004
5559 Background: Point mutations in RET tyrosine kinase, most commonly C634R and M918T, result in the development of medullary…
Expand
2009
2009
2008—down, but not out
Walter Yang
Nature Biotechnology
2009
Corpus ID: 30534589
Researcher Investor Value ($ millions) Deal description Actelion GlaxoSmithKline $3,246.8 Co-develop and co-commercialize phase 3…
Expand
2008
2008
Motesanib for Thyroid Cancer
B. Murphy
2008
Corpus ID: 80111459
Iodine-refractory differentiated thyroid cancer, whether locally recurrent or metastatic, is notoriously resistant to systemic…
Expand
2008
2008
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2008
Corpus ID: 9963020
Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following…
Expand